I. Voutsas

发表

Toll-like receptor agonists: current status and future perspective on their utility as adjuvants in improving anticancer vaccination strategies.

O. Tsitsilonis, C. Baxevanis, I. Voutsas, 2013, Immunotherapy.

Gamma-irradiation induces HER-2/neu overexpression in breast cancer cell lines and sensitivity to treatment with trastuzumab

S. Perez, A. Gritzapis, C. Baxevanis, 2013, International journal of radiation biology.

Chemotherapy ± Cetuximab Modulates Peripheral Immune Responses in Metastatic Colorectal Cancer

A. Gritzapis, I. Voutsas, C. Kosmas, 2013, Oncology.

MHC class II tetramer analyses in AE37-vaccinated prostate cancer patients reveal vaccine-specific polyfunctional and long-lasting CD4+ T-cells

S. Perez, M. Papamichail, C. Baxevanis, 2016, Oncoimmunology.

Ontak reduces the immunosuppressive tumor environment and enhances successful therapeutic vaccination in HER-2/neu-tolerant mice

A. Gritzapis, C. Baxevanis, I. Voutsas, 2012, Cancer Immunology, Immunotherapy.

T-Cell Repertoire in Tumor Radiation: The Emerging Frontier as a Radiotherapy Biomarker

A. Gritzapis, C. Baxevanis, I. Voutsas, 2022, Cancers.

Unraveling the role of preexisting immunity in prostate cancer patients vaccinated with a HER-2/neu hybrid peptide

S. Perez, M. Papamichail, C. Baxevanis, 2016, Journal of Immunotherapy for Cancer.

Ii-Key/HER-2/neu(776-90) hybrid peptides induce more effective immunological responses over the native peptide in lymphocyte cultures from patients with HER-2/neu+ tumors

S. Perez, N. Kallinteris, A. Gritzapis, 2007, Cancer Immunology, Immunotherapy.

Tumor-Specific CD4+ T Lymphocytes from Cancer Patients Are Required for Optimal Induction of Cytotoxic T Cells Against the Autologous Tumor

O. Tsitsilonis, A. Gritzapis, M. Papamichail, 2000, Journal of Immunology.

Autologous Tumor Induction of Cytotoxic T Cells Against the Cancer Patients Are Required for Optimal T Lymphocytes from + Tumor-Specific CD4

A. Gritzapis, C. Baxevanis, I. Voutsas, 2000 .

Peptide vaccination breaks tolerance to HER-2/neu by generating vaccine-specific FasL(+) CD4(+) T cells: first evidence for intratumor apoptotic regulatory T cells.

A. Gritzapis, M. Papamichail, C. Baxevanis, 2010, Cancer research.

Ovarian malignant ascites-derived lymphocytes stimulated with prothymosin α or its immunoactive decapeptide lyse autologous tumour cells in vitro and retard tumour growth in SCID mice.

M. Dimopoulos, O. Tsitsilonis, T. Katsila, 2012, European journal of cancer.

Increased generation of autologous tumor-reactive lymphocytes by anti-CD3 monoclonal antibody and prothymosin α

O. Tsitsilonis, A. Mamalaki, G. Spanakos, 1999, Cancer Immunology, Immunotherapy.

Immune profiling of melanoma tumors reflecting aggressiveness in a preclinical model

S. Perez, C. Baxevanis, I. Voutsas, 2017, Cancer Immunology, Immunotherapy.

Aldehyde Dehydrogenase Enzyme Functions in Acute Leukemia Stem Cells.

Garrett M. Dancik, G. Dancik, S. Vlahopoulos, 2022, Frontiers in bioscience.

Compromised anti‐tumor responses in tumor necrosis factor‐α knockout mice

O. Tsitsilonis, A. Gritzapis, M. Papamichail, 2000, European journal of immunology.

The immunologically active site of prothymosin α is located at the carboxy-terminus of the polypeptide. Evaluation of its in vitro effects in cancer patients

O. Tsitsilonis, A. Bamias, M. Neagu, 2006, Cancer Immunology, Immunotherapy.

Further insight into AE37 peptide vaccination in prostate cancer

I. Voutsas, E. Anastasopoulou, 2017, Future science OA.

A flow cytometric approach for studying alterations in the cytoplasmic concentration of calcium ions in immune cells following stimulation with thymic peptides.

O. Tsitsilonis, P. Samara, I. Voutsas, 2016, Cellular immunology.

MISTLETOE LECTIN I-INDUCED EFFECTS ON HUMAN CYTOTOXIC LYMPHOCYTES. I. SYNERGISM WITH LAK CYTOTOXICITY. IL-2 IN THE INDUCTION OF ENHANCED

O. Tsitsilonis, A. Gritzapis, C. Baxevanis, 1998 .

Mistletoe lectin I-induced effects on human cytotoxic lymphocytes. I. Synergism with IL-2 in the induction of enhanced LAK cytotoxicity.

O. Tsitsilonis, W. Voelter, A. Gritzapis, 1998, Immunopharmacology and immunotoxicology.

The prognostic value of alpha-thymosins in breast cancer.

C. Markopoulos, J. Gogas, O. Tsitsilonis, 1998, Anticancer research.

Combining immunological and molecular data to assess phylogenetic relations of some Greek Podarcis species.

O. Tsitsilonis, P. Lymberakis, I. Voutsas, 2007, Comparative biochemistry and physiology. Part B, Biochemistry & molecular biology.

Synergy between interleukin-2 and prothymosin α for the increased generation of cytotoxic T lymphocytes against autologous human carcinomas

A. Gritzapis, M. Papamichail, C. Baxevanis, 2000, Cancer Immunology, Immunotherapy.

Lower RNA expression of ALDH1A1 distinguishes the favorable risk group in acute myeloid leukemia

Garrett M. Dancik, S. Vlahopoulos, I. Voutsas, 2021, Molecular Biology Reports.

Combined treatment with Bevacizumab and standard chemotherapy restores abnormal immune parameters in advanced colorectal cancer patients

A. Gritzapis, C. Baxevanis, I. Voutsas, 2012, Investigational New Drugs.

A novel quantitative flow cytometric method for measuring glucocorticoid receptor (GR) in cell lines: correlation with the biochemical determination of GR.

M. Alexis, S. Perez, A. Gritzapis, 2007, Journal of immunological methods.

Immune biomarkers: how well do they serve prognosis in human cancers?

S. Perez, M. Papamichail, C. Baxevanis, 2015, Expert review of molecular diagnostics.

AQ2 Immune biomarkers: how well do they serve as

S. Perez, M. Papamichail, I. Voutsas, 2015 .

Compromised anti-tumor responses in tumor necrosis factor-alpha knockout mice.

O. Tsitsilonis, A. Gritzapis, C. Baxevanis, 2000, European journal of immunology.

HER-2/neu as a target for cancer vaccines.

S. Perez, A. Gritzapis, M. Papamichail, 2010, Immunotherapy.

Identification of a Novel Immunogenic HLA-A*0201-Binding Epitope of HER-2/neu with Potent Antitumor Properties1

S. Perez, A. Gritzapis, M. Papamichail, 2008, The Journal of Immunology.

with Potent Antitumor Properties HLA-A*0201-Binding Epitope of HER-2/neu Identification of a Novel Immunogenic

S. Perez, M. Papamichail, C. Baxevanis, 2013 .

Potent Antitumor Properties neu HLA-A * 0201-Binding Epitope of HER-2 / Identification of a Novel Immunogenic

S. Perez, A. Gritzapis, M. Papamichail, 2008 .

Induction of potent CD4+ T cell‐mediated antitumor responses by a helper HER‐2/neu peptide linked to the Ii‐Key moiety of the invariant chain

N. Kallinteris, A. Gritzapis, C. Baxevanis, 2007, International journal of cancer.

New use for old drugs? Prospective targets of chloroquines in cancer therapy.

G. Chrousos, S. Vlahopoulos, E. Critselis, 2014, Current drug targets.

Potential Prognostic Molecular Signatures in a Preclinical Model of Melanoma.

S. Perez, C. Baxevanis, I. Voutsas, 2017, Anticancer research.

A pilot study in prostate cancer patients treated with the AE37 Ii-key-HER-2/neu polypeptide vaccine suggests that HLA-A*24 and HLA-DRB1*11 alleles may be prognostic and predictive biomarkers for clinical benefit

H. Kalbacher, S. Perez, M. Papamichail, 2015, Cancer Immunology, Immunotherapy.

Frequencies of an Immunogenic HER-2/neu Epitope of CD8+ T Lymphocytes Predict Favorable Clinical Outcomes in Prostate Cancer

A. Gritzapis, C. Baxevanis, I. Voutsas, 2023, International journal of molecular sciences.

Prothymosin Alpha: An Alarmin and More...

O. Tsitsilonis, H. Kalbacher, P. Samara, 2017, Current medicinal chemistry.

Immune profiling of melanoma tumors reflecting aggressiveness in a preclinical model

S. Perez, C. Baxevanis, I. Voutsas, 2017, Cancer Immunology, Immunotherapy.